Naloxone Hydrochloride (DBL) is a medicine containing the active ingredient(s) naloxone. On this page you will find out more about Naloxone Hydrochloride (DBL), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: naloxone
Information for medicine and pack size:
Naloxone Hydrochloride (DBL) 400 microgram/mL injection solution, 5 x 1 mL ampoules
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
This product accepted for registration as 'currently supplied' at the time of commencement of the Act. Approval for listing of these goods as Pharmaceutical Benefits were approved as specified in the letter of 29 October 1992 from Dr Alex Proudfoot. Indications: For the complete or partial reversal of narcotic depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone and the narcotic-antagonist analgesics such as nalbuphine, methadone and butorphanol. INDICATIONS AS AT 8 January 2004: Naloxone is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, codeine, morphine and heroin, and the mixed opioid agonist-antagonist analgesics such as pentazocine. Naloxone is also indicated for the diagnosis of suspected acute opioid overdosage.
Table of characteristics
|Visual appearance||Clear, colourless liquid free from visible particulate matter.|
|Dosage Form||Injection, solution|
|Route of administration||Intravenous|
5x400 microgram/1mL: Prescription Only Medicine, or Prescription Animal Remedy
5x400 microgram/1mL(E): Not scheduled. Not considered by committee
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Protect from Light|
|Life time||2 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 January 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Found 1 results
DBL Naloxone Hydrochloride Injection (Solution for injection) - myDr.com.au
DBL Naloxone Hydrochloride Injection (Solution for injection) - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 0 results